GLUE
Monte Rosa Therapeutics Inc

1,237
Mkt Cap
$1.12B
Volume
632,819.00
52W High
$18.15
52W Low
$3.50
PE Ratio
54.22
GLUE Fundamentals
Price
$16.56
Prev Close
$17.23
Open
$17.34
50D MA
$12.80
Beta
1.56
Avg. Volume
971,773.53
EPS (Annual)
-$0.9836
P/B
4.16
Rev/Employee
$564,343.28
Loading...
Loading...
News
all
press releases
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week High - Still a Buy?
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year High - Still a Buy...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
GLUE Crosses Above Average Analyst Target
In recent trading, shares of Monte Rosa Therapeutics Inc (Symbol: GLUE) have crossed above the average analyst 12-month target price of $17.20, changing hands for $17.26/share. When a stock reaches...
Nasdaq News: Markets·7d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week High - Here's Why
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week High - Here's What Happened...
MarketBeat·8d ago
News Placeholder
Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE
Hillsdale Investment Management Inc. acquired a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing...
MarketBeat·16d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - Should You Buy?
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week High - Here's What Happened...
MarketBeat·17d ago
News Placeholder
Integrated Quantitative Investments LLC Acquires New Holdings in Monte Rosa Therapeutics, Inc. $GLUE
Integrated Quantitative Investments LLC bought a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the second quarter, according to its most recent filing with the...
MarketBeat·23d ago
News Placeholder
22,500 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Bailard Inc.
Bailard Inc. bought a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange...
MarketBeat·25d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - Here's Why
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - What's Next...
MarketBeat·29d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Here's Why
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Should You Sell...
MarketBeat·30d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% Following Analyst Upgrade
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% on Analyst Upgrade...
MarketBeat·1mo ago

Latest GLUE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.